**Friday 8 January 2016**

16.30: **Welcome and introduction**

by local faculty and introduction of local faculty members

16.40: **Welcome of attendees: welcome video message**

from Silke Gillessen

16.50: **Welcome of attendees: welcome video message**

from the DUOS board

16.55: **Case presentation + interactive voting**

17.00:  **General Session 1: Prostate Cancer Local Therapy**

**David P. Dearnaley**

Abstract 2: Comparison of hypofractionated high-dose intensity-modulated

radiotherapy schedules for prostate cancer: Results from the phase III randomized

CHHiP trial (CRUK/06/016).

17.15:  **Oral Abstract Session A: Prostate Cancer**

**Howard I. Scher**

Abstract 163: Single CTC characterization identifies phenotypic and genomic

heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx)

in mCRPC patients.

17.30: **General Session 1: Prostate Cancer Local Therapy**

**Ronald C. Chen**

Management of Patients with Radiologically or Pathologically Involved Lymph Nodes:

Roles of Radiotherapy, Surgery, and Systemic Treatment

18.00: **Live connection with ASCO GU speakers in San Francisco**

- Introduction of highlights of the Thursday Congress program

 - Q&A with international speakers from the congress

18.40: **Oral Abstract Session A: Prostate Cancer**

**William U. Shipley**

Abstract 3: NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients:

 Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation

 therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

19.00: **General Session 2: Potential Targets for Advanced Prostate Cancer**

**Tomasz M. Beer**

Integrative Clinical Genomics in Castrate-Resistant Prostate Cancer

19.20: **General Session 2: Potential Targets for Advanced Prostate Cancer**

**Johann S. De Bono**

Novel Targets for Castrate-Resistant Prostate Cancer

19.40: **General Session 2: Potential Targets for Advanced Prostate Cancer**

**Nima Sharifi**

Androgen Receptor: New Ways of Targeting the Old Target

20.00: **Wrap-up and preview of Saturday program**

20.10: **Dinner**

**Saturday 9 Januari 2016**

09.00: **Start and introduction of day 2 program**

09.10: **Oncology News Program – Early stage PCa**

09.30: **Prostate Cancer: Year in Review and Keynote Lecture**

**Maha Hussain**

Keynote Lecture: Changes in the Treatment of Hormone-Naive Disease

9.50: **General Session 3: Bone Metastases: Biology, Treatment, and Palliation (ARS)**

**Kenneth J. Pienta**

**Biology of Bone Metastases**

10.10: **General Session 3: Bone Metastases: Biology, Treatment, and Palliation (ARS)**

**Matthew R. Smith**

Best Use of Approved Therapies for Bone Metastases

10.35: **Break**

10.50: **Oncology News Program – metastatic PCa**

11.10: **Discussion**

11.25:  **General Session 4: Immunotherapy for Urothelial Carcinoma**

**Bishoy Faltas**

Abstract 354: Generating a neoantigen map of advanced urothelial carcinoma by

whole exome sequencing.

11.40: **General Session 4: Immunotherapy for Urothelial Carcinoma**

**Jean Hoffman-Censits**

Abstract 355: IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-

treated locally advanced or metastatic urothelial carcinoma (mUC).

11.55: **General Session 4: Immunotherapy for Urothelial Carcinoma**

**Padmanee Sharma**

State of Predictive Biomarkers and Response to Immunotherapy in Advanced Disease

12.15: **Discussion and interactive voting**

12.30: **Lunch**

13.30:  **Urothelial Carcinomas: Year in Review and Keynote Lecture​**

**Nicholas D. James**

Year in Review

14.05: **Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers**

**Mohamed Zaghloul**

Abstract 356: A randomized clinical trial comparing adjuvant radiation versus

chemo-RT versus chemotherapy alone after radical cystectomy for locally

advanced bladder cancer.

14.20: **Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers**

**Matt D. Galsky**

Abstract 357: Phase II trial of gemcitabine + cisplatin + ipilimumab in patients

with metastatic urothelial cancer.

14.35: **Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers**

**Guru Sonpavde**

Abstract 358: Circulating cell-free DNA profiling of patients with advanced

urothelial carcinoma.

14.50: **Oncology News Program - urothelial cancer**

15.10: **Break**

15.30: **Live connection with San Francisco**

- Session 1: Review of local therapy and advanced prostate cancer

 - Session: Genomics/androgen receptor and urothelial bladder

16.45: **Additional live connection** with local faculty members André Bergman (NL) and Steven Joniau (BE)

17.00: **Close and evaluation**